News of an analyst's price-target hike plus a new round of capital-raising were the sparks that ignited Janux Therapeutics (JANX 11.65%) stock on Wednesday. The clinical-stage biotech's share price ended the day nearly 12% higher, and this was on a very good day for the exchange with the S&P 500 rising by 0.6%.

Price-target raised, new shares floated

Well before market open, Scotiabank pundit George Farmer aggressively raised his price target on Janux, cranking it nearly 50% higher to $62 per share. That doesn't necessarily make him a bull, though, as he maintained his recommendation of sector perform (hold, in other words).

According to reports, Farmer wrote that the biotech company's current phase 1 trial of its JANX007 prostate cancer treatment is rather promising so far. That said, the analyst believes Janux hasn't yet honed a sharp competitive edge and isn't yet an attractive enough target for a pharmaceutical company to acquire it.

What Janux has done, however, is push to extend its runway with a fresh share issue. After market hours Tuesday, the company said it had launched a $300 million secondary common stock flotation. Certain investors will have the option of purchasing pre-funded warrants instead of shares, and the issue's underwriters are expected to be granted a 30-day option to purchase an additional $45 million worth of shares collectively.

A promising future?

Janux said it aims to use its proceeds from the share issue "to advance clinical development of its internal product pipeline," in addition to general corporate purposes.

The company focuses on cancer treatments, which continues to be a hot area for biotechs, but Farmer makes a good point that Janux hasn't distinguished itself sufficiently. However, it's a relatively young enterprise, and those recent clinical readouts are encouraging.